Sigyn Therapeutics Stock Performance
| SIGY Stock | USD 0.75 0.13 20.97% |
The entity has a beta of 1.07, which indicates a somewhat significant risk relative to the market. Sigyn Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Sigyn Therapeutics is expected to follow. At this point, Sigyn Therapeutics has a negative expected return of -0.7%. Please make sure to validate Sigyn Therapeutics' standard deviation, potential upside, as well as the relationship between the Potential Upside and day typical price , to decide if Sigyn Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Sigyn Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's technical and fundamental indicators remain fairly strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 84.4 K | |
| Total Cashflows From Investing Activities | -29.3 K |
Sigyn |
Sigyn Therapeutics Relative Risk vs. Return Landscape
If you would invest 200.00 in Sigyn Therapeutics on November 18, 2025 and sell it today you would lose (125.00) from holding Sigyn Therapeutics or give up 62.5% of portfolio value over 90 days. Sigyn Therapeutics is currently does not generate positive expected returns and assumes 12.5919% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Sigyn, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sigyn Therapeutics Target Price Odds to finish over Current Price
The tendency of Sigyn OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.75 | 90 days | 0.75 | about 87.71 |
Based on a normal probability distribution, the odds of Sigyn Therapeutics to move above the current price in 90 days from now is about 87.71 (This Sigyn Therapeutics probability density function shows the probability of Sigyn OTC Stock to fall within a particular range of prices over 90 days) .
Sigyn Therapeutics Price Density |
| Price |
Predictive Modules for Sigyn Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Sigyn Therapeutics. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sigyn Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Sigyn Therapeutics is not an exception. The market had few large corrections towards the Sigyn Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Sigyn Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Sigyn Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.72 | |
β | Beta against Dow Jones | 1.07 | |
σ | Overall volatility | 0.56 | |
Ir | Information ratio | -0.06 |
Sigyn Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Sigyn Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Sigyn Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Sigyn Therapeutics generated a negative expected return over the last 90 days | |
| Sigyn Therapeutics has high historical volatility and very poor performance | |
| Sigyn Therapeutics has some characteristics of a very speculative penny stock | |
| Sigyn Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Sigyn Therapeutics currently holds 1.21 M in liabilities with Debt to Equity (D/E) ratio of 2.72, implying the company greatly relies on financing operations through barrowing. Sigyn Therapeutics has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Sigyn Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Sigyn Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sigyn Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sigyn to invest in growth at high rates of return. When we think about Sigyn Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (3 M) with loss before overhead, payroll, taxes, and interest of (536.05 K). | |
| Sigyn Therapeutics currently holds about 7.29 K in cash with (1.77 M) of positive cash flow from operations. | |
| Roughly 77.0% of Sigyn Therapeutics outstanding shares are owned by corporate insiders |
Sigyn Therapeutics Fundamentals Growth
Sigyn OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Sigyn Therapeutics, and Sigyn Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sigyn OTC Stock performance.
| Return On Equity | -25.64 | |||
| Return On Asset | -1.94 | |||
| Current Valuation | 11.06 M | |||
| Shares Outstanding | 37.3 M | |||
| Price To Book | 39.04 X | |||
| Price To Sales | 114.95 X | |||
| EBITDA | (2.53 M) | |||
| Cash And Equivalents | 7.29 K | |||
| Total Debt | 1.21 M | |||
| Debt To Equity | 2.72 % | |||
| Book Value Per Share | (0.05) X | |||
| Cash Flow From Operations | (1.77 M) | |||
| Earnings Per Share | (0.09) X | |||
| Total Asset | 710.26 K | |||
About Sigyn Therapeutics Performance
Evaluating Sigyn Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Sigyn Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sigyn Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin peptidoglycan and lipoteichoic acid viral pathogens hepatic toxins CytoVesicles and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. Sigyn Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5 people.Things to note about Sigyn Therapeutics performance evaluation
Checking the ongoing alerts about Sigyn Therapeutics for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Sigyn Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sigyn Therapeutics generated a negative expected return over the last 90 days | |
| Sigyn Therapeutics has high historical volatility and very poor performance | |
| Sigyn Therapeutics has some characteristics of a very speculative penny stock | |
| Sigyn Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Sigyn Therapeutics currently holds 1.21 M in liabilities with Debt to Equity (D/E) ratio of 2.72, implying the company greatly relies on financing operations through barrowing. Sigyn Therapeutics has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Sigyn Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Sigyn Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sigyn Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sigyn to invest in growth at high rates of return. When we think about Sigyn Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (3 M) with loss before overhead, payroll, taxes, and interest of (536.05 K). | |
| Sigyn Therapeutics currently holds about 7.29 K in cash with (1.77 M) of positive cash flow from operations. | |
| Roughly 77.0% of Sigyn Therapeutics outstanding shares are owned by corporate insiders |
- Analyzing Sigyn Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sigyn Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Sigyn Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sigyn Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sigyn Therapeutics' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Sigyn Therapeutics' otc stock. These opinions can provide insight into Sigyn Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Sigyn OTC Stock Analysis
When running Sigyn Therapeutics' price analysis, check to measure Sigyn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sigyn Therapeutics is operating at the current time. Most of Sigyn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sigyn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sigyn Therapeutics' price. Additionally, you may evaluate how the addition of Sigyn Therapeutics to your portfolios can decrease your overall portfolio volatility.